Cyproterone Acetate and Risk of Meningioma: A Nationwide Cohort Study

In a nationwide Danish cohort study, researchers investigated the association between the use of Cyproterone acetate (CPA) and the risk of developing meningioma. The study included individuals born between 1930 and 2000, who were followed from age 15, immigration to Denmark, or January 1, 1995, until a diagnosis of meningioma, neurofibromatosis type 2, death, emigration, or December 31, 2017. Those with prior meningioma, intracranial surgery, neurofibromatosis type 2, or who died before inclusion were excluded. The study found that females exposed to high cumulative doses of CPA had a 6–20 fold increased risk of meningioma compared to those exposed to low cumulative doses, leading the European Medicines Agency (EMA) to recommend restricting CPA use to less than 10 milligrams per day.